Faeth Therapeutics to Join Jefferies Investor Conference

Faeth Therapeutics, a clinical-stage biotechnology firm, recently announced that CEO Anand Parikh will engage in one-on-one investor meetings at the Jefferies Global Healthcare Conference in New York from June 4-6. Faeth, co-founded by prominent oncology researchers Drs. Lew Cantley, Siddhartha Mukherjee, and Karen Vousden alongside Parikh, is pioneering new cancer treatments by focusing on cancer metabolism, a critical yet under-explored area in oncology.

The company's innovative approach integrates a comprehensive understanding of cancer metabolism, functional genomics, and computational biology to create more effective and less toxic therapies. Central to Faeth's research and development efforts is its MetabOS discovery platform, which utilizes artificial intelligence (AI), machine learning, and curated datasets to pinpoint targets specific to various tumor genotypes.

Faeth’s flagship program, known as PIKTOR (FTH-001/003), involves the combined use of serabelisib, a PI3Kɑ inhibitor, and sapanisertib, an mTORC 1/2 inhibitor. This combination is designed to effectively inhibit the PI3K pathway, a pathway frequently mutated in cancerous cells. In Phase 1b clinical trials, PIKTOR demonstrated remarkable efficacy, particularly in treating endometrial, ovarian, and breast cancers, when used in conjunction with paclitaxel.

Additionally, Faeth's second clinical program, FTH-002, introduces a specially formulated amino acid sachet. This sachet is intended to be used alongside an amino acid-restricted diet and traditional radio/chemotherapy treatments, potentially enhancing the effectiveness of these treatments.

Faeth's impressive clinical and preclinical pipeline is driven by its proprietary MetabOS discovery platform. This state-of-the-art platform harnesses the power of AI and machine learning to analyze vast amounts of data, enabling the identification of optimal treatment targets that correspond to specific genetic profiles of tumors.

Looking ahead, Faeth plans to advance its lead program, PIKTOR, into a Phase 2 trial specifically targeting endometrial cancer in 2024. The company continues to focus on developing groundbreaking therapies that exploit cancer metabolism to not only halt the proliferation of cancer cells but also to do so with reduced toxicity compared to traditional treatments.

By leveraging their systemic understanding of cancer metabolism, the founders and team at Faeth are positioned at the cutting edge of cancer treatment research. Their collaborative efforts aim to revolutionize how cancer is treated, making therapies safer and more personalized.

In summary, Faeth Therapeutics is making significant strides in oncology research with its innovative focus on cancer metabolism. By utilizing advanced AI technologies and understanding the genetic underpinnings of tumors, Faeth aims to deliver new therapies that could potentially transform the landscape of cancer treatment, offering hope to many patients.